ArticleSurgical neurology international2013
Anesthetic drug development: Novel drugs and new approaches.
Article in Surgical neurology international, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 51 citations in OpenAlex.
- Effects of different doses of remimazolam besylate on postoperative sedation, pain, and adverse reactions in patients undergoing hysteroscopic surgery.BMC surgery · 2025Trial
- Comparison of remimazolam tosilate and propofol during induction and maintenance of general anesthesia in patients undergoing laparoscopic cholecystectomy: a prospective, single center, randomized controlled trial.BMC anesthesiology · 2024Trial
- Efficacy and safety of remimazolam versus propofol for general anesthesia: a multicenter, single-blind, randomized, parallel-group, phase IIb/III trial.Journal of anesthesia · 2020Trial
- Feasibility of remimazolam rescue sedation for neonatal MRI: a case report.BMC anesthesiology · 2026Article
- General Anesthetics: Aspects of Chirality, Pharmacodynamics, and Pharmacokinetics.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Recent progress in the development of etomidate analogues.Frontiers in pharmacology · 2025Review
- The effective sedative dose of remimazolam for BIS <60 during general anesthesia induction between elderly and non-elderly patients-A randomized controlled trial.Frontiers in pharmacology · 2025Article
- Experimental study of local anesthetic and antiarrhythmic activities of fluorinated ethynylpiperidine derivatives.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2024Article
- Sevoflurane Exposure in Neonates Perturbs the Expression Patterns of Specific Genes That May Underly the Observed Learning and Memory Deficits.International journal of molecular sciences · 2023Article
- Heptanol-mediated phase separation determines phase preference of molecules in live cell membranes.Journal of lipid research · 2022Article
- Novel ultrashort-acting benzodiazepine remimazolam lowers shivering threshold in rabbits.Frontiers in pharmacology · 2022Article
- Anesthetic management using remimazolam in a patient with atrial flutter: a case report.American journal of translational research · 2022Article
- Neonatal administration of a subanaesthetic dose of JM-1232(-) in mice results in no behavioural deficits in adulthood.Scientific reports · 2021Article
- Achievements in Thermosensitive Gelling Systems for Rectal Administration.International journal of molecular sciences · 2021Review
- Discovery of the EL-0052 as a potential anesthetic drug.Computational and structural biotechnology journal · 2021Article
- High-throughput Screening in Larval Zebrafish Identifies Novel Potent Sedative-hypnotics.Anesthesiology · 2018Article
- Novel positive allosteric modulators of GABAA receptors with anesthetic activity.Scientific reports · 2016Article
- Macroscopic and macromolecular specificity of alkylphenol anesthetics for neuronal substrates.Scientific reports · 2015Article
- Reawakening anaesthesia research.EMBO reports · 2014Article
- Remimazolam: The future of its sedative potential.Saudi journal of anaesthesia · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The ideal sedative-hypnotic drug would be a rapidly titratable intravenous agent with a high therapeutic index and minimal side effects. The current efforts to develop such agents are primarily focused on modifying the structures of existing drugs to improve their pharmacodynamic and pharmacokinetic properties. Drugs currently under development using this rational design approach include analogues of midazolam, propofol, and etomidate, such as remimazolam, PF0713, and cyclopropyl methoxycarbonyl-etomidate (MOC-etomidate), respectively. An alternative approach involves the rapid screening of large libraries of molecules for activity in structural or phenotypic assays that approximate anesthetic and target receptor interactions. Such high-throughput screening offers the potential for identifying completely novel classes of drugs. Anesthetic drug development is experiencing a resurgence of interest because there are new demands on our clinical practice that can be met, at least in part, with better agents. The goal of this review is to provide the reader with a glimpse of the novel anesthetic drugs and new developmental approaches that lie on the horizon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.